124 related articles for article (PubMed ID: 36994687)
21. A Comprehensive Pan-Cancer Analysis of the Tumorigenic Role of Matrix Metallopeptidase 7 (MMP7) Across Human Cancers.
Meng N; Li Y; Jiang P; Bu X; Ding J; Wang Y; Zhou X; Yu F; Zhang Y; Zhang J; Xia L
Front Oncol; 2022; 12():916907. PubMed ID: 35785154
[TBL] [Abstract][Full Text] [Related]
22. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
[TBL] [Abstract][Full Text] [Related]
23. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.
Ma J; Jin Y; Gong B; Li L; Zhao Q
Discov Oncol; 2022 Mar; 13(1):17. PubMed ID: 35312867
[TBL] [Abstract][Full Text] [Related]
24. NOP16 promotes hepatocellular carcinoma progression and triggers EMT through the Keap1-Nrf2 signaling pathway.
Mu S; Tian Q; Shen L
Technol Health Care; 2024 Jan; ():. PubMed ID: 38251077
[TBL] [Abstract][Full Text] [Related]
25. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
26. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of RAB13 expression in pan-cancer based on multi-databases integrative analysis.
Zhang XD; Liu ZY; Luo K; Wang XK; Wang MS; Huang S; Li RF
Sci Rep; 2023 Oct; 13(1):16859. PubMed ID: 37803063
[TBL] [Abstract][Full Text] [Related]
28. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
Qin P; Huang H; Wang J; Jiang T; Zeng N; Wang Q; He Y; Zhou Y
Med Oncol; 2023 Aug; 40(9):276. PubMed ID: 37612479
[TBL] [Abstract][Full Text] [Related]
29. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.
Zhang MH; Liu J
Bioengineered; 2022 Apr; 13(4):10047-10060. PubMed ID: 35412944
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma.
Li S; Xue P; Diao X; Fan QY; Ye K; Tang XM; Liu J; Huang ZY; Tang QH; Jia CY; Xin R; Lv ZW; Liu JB; Ma YS; Fu D
J Adv Res; 2023 Dec; 54():133-146. PubMed ID: 36716957
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
Yang Y; Zhao W; Du J; Wang Y
Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
[TBL] [Abstract][Full Text] [Related]
33. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
Li L; Feng Q; Wang X
Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
[TBL] [Abstract][Full Text] [Related]
34. Identification of
Zheng R; Zhu HL; Hu BR; Ruan XJ; Cai HJ
World J Clin Cases; 2020 Jul; 8(14):2917-2929. PubMed ID: 32775374
[TBL] [Abstract][Full Text] [Related]
35. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
[TBL] [Abstract][Full Text] [Related]
36. Systematic analysis of the prognostic and immunological role of DHX33 in pan-cancer.
Ding J; Zhou J; Shen X; Zhang M; Feng X; Xu Z
Environ Toxicol; 2023 Aug; 38(8):2011-2021. PubMed ID: 37256545
[TBL] [Abstract][Full Text] [Related]
37. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
38. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
[TBL] [Abstract][Full Text] [Related]
39. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
[TBL] [Abstract][Full Text] [Related]
40. GIV is a promising novel poor prognostic factor in liver hepatocellular carcinoma.
Zou Z; Sun Y; Wang L; Ma S; Sun C; Zhou Y; Yang G
Medicine (Baltimore); 2022 Aug; 101(32):e29645. PubMed ID: 35960100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
